InsiderTrades

Form 4 for INBX Inhibrx Biosciences, Inc.

Accepted 2024-05-30 00:00:00 ET · period of report 2024-05-29 · accession 0000950142-24-001492 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMI 2024-05-30 2024-05-29 INBX Kayyem Jon Faiz Dir A - Grant — +818.6K 6,250 New —
D 2024-05-30 2024-05-30 INBX Kayyem Jon Faiz Dir A - Grant $0.00 +30.0K 30.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-05-29 A A 6,250 — 6,250 I By Child B — — (F1) The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. (F4) These securities are held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child B. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
2 Common Common Stock 2024-05-29 A A 806,075 — 806,075 I By The Jon F. Kayyem and Paige Gates-Kayyem Family Trust — — (F1) The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. (F2) These securities are directly owned by The Jon F. Kayyem and Paige Gates-Kayyem Family Trust. Jon Faiz Kayyem is the trustee of The Jon F. Kayyem and Paige Gates-Kayyem Family Trust and he disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
3 Common Common Stock 2024-05-29 A A 6,250 — 6,250 I By Child A — — (F1) The transactions reported herein are the result of the consummation on May 29, 2024 of the distribution by Inhibrx, Inc. of 92% of the issued and outstanding shares of common stock of its subsidiary, Inhibrx Biosciences, Inc. (the "Issuer"), to holders of shares of Inhibrx, Inc.'s common stock as of the distribution record date of May 17, 2024, on a pro rata basis, at a ratio of one share of the Company's common stock for every four shares of Inhibrx, Inc.'s issued and outstanding common stock held on the distribution record date. These transactions are voluntarily reported notwithstanding the exemption provided by Rule 16a-9. (F3) These securities are held in a custodial account managed by the reporting person for the benefit of the reporting person's minor child, Child A. The reporting person disclaims beneficial ownership of these securities, except to the extent of any indirect pecuniary interest in his distributive shares therein.
4 Derivative Stock Option (right to buy) 2024-05-30 A A 30,000 $0.00 30,000 D $15.86 · — to 2034-05-30 30,000 Common Stock (F5) This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi. (F6) This stock option will be fully exercisable on May 30, 2025, subject to the reporting person?s continued service through such date.